Sign in
ANNX Stock Price, Chart, Stats & News
Annexon, Inc.
Save
Annexon, Inc. (ANNX) does not currently pay a dividend.
693.05M
Market cap
–
Current P/E
–
Forward P/E
ANNX chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -90.35% |
ROE | -92.28% |
D/E | 0.17x |
Interest coverage ratio | – |
ANNX valuation
P/E | – |
P/S | – |
P/B | 4.62x |
P/CF | -4.23x |
P/FCF | -3.39x |
P/OCF | -4.23x |
PEG | 0.39x |
EV multiple | -3.32x |
About
Annexon, Inc. is a biopharmaceutical company currently engaged in clinical trials, dedicated to the discovery and advancement of therapies for a variety of autoimmune, neurodegenerative, and ophthalmic conditions. Central to its approach is the C1q molecule, which initiates the classical complement pathway. The company targets this pathway to address specific disease mechanisms, such as those seen in antibody-mediated autoimmune disorders and complement-driven neurodegeneration.
Similar securities
Based on sector and market capitalization
Report issue